Evidence Hub

Natural phenolic compounds as modulators of radiation response in hepatocellular carcinoma

Imani A, Rassouli FB

Clinical and experimental medicine, 2026

Abstract

Radiotherapy remains a cornerstone in the treatment of hepatocellular carcinoma (HCC), yet its clinical efficacy is constrained by the intrinsic radioresistance of liver tumors and the dose-limiting toxicity to surrounding healthy tissue. Natural phenolic compounds (NPCs), including flavonoids (apigenin, genistein, quercetin, fisetin, wogonin, isoliquiritigenin, corylin and epigallocatechin gallate) and other classes (ellagic acid, ferulic acid, chlorogenic acid, pterostilbene, resveratrol, magnolol, curcumin, liensinine, emodin, verbascoside and caffeic acid phenethyl ester), have emerged as promising agents to expand this therapeutic window. Evidence suggests that many NPCs enhance radiosensitivity in HCC cells through convergent mechanisms such as disrupting redox homeostasis to impair Nrf2-mediated antioxidant defenses, inhibiting DNA repair pathways, and reversing hypoxia-driven metabolic reprogramming. Nevertheless, radiosensitizing effects of NPCs is context-dependent, for instance, resveratrol (under hypoxic condition) and chlorogenic acid have demonstrated radioprotective properties, potentially counteracting therapeutic goals. Additionally, methodological limitations-including the use of misidentified cell lines-raise concerns about the reliability of the reported safety and selectivity outcomes for NPCs. Translational success will hinge on overcoming challenges such as poor bioavailability, which may be addressed through tumor-microenvironment-responsive…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free